Home / Companies / BMY / Catalysts / Page 3 Catalysts · BMY · CIK 14272 · page 3 of 3 BMY catalysts and FDA events, page 3. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on BMY PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source August 4, 2025 RHUPH20 BMY Primary completion Melanoma Completed ClinicalTrials.gov August 1, 2025 luspatercept (ACE-536) BMY Primary completion Beta-thalassemia Completed ClinicalTrials.gov July 31, 2025 — BMY Earnings — Completed SEC 8-K Exhibit 99.1 July 29, 2025 Opdivo® (nivolumab) BMY Primary completion Clear Cell Renal Cell Carcinoma Completed ClinicalTrials.gov July 14, 2025 lonsurf (TAS-102) BMY Primary completion Colorectal Neoplasms Withdrawn ClinicalTrials.gov June 23, 2025 — BMY PDUFA date — Scheduled SEC Form 10-Q May 26, 2025 luspatercept (ACE-536) BMY Primary completion Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis Completed ClinicalTrials.gov May 23, 2025 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 23, 2025 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA May 22, 2025 Opdivo® (nivolumab) BMY Primary completion Extensive-stage Small Cell Lung Cancer Completed ClinicalTrials.gov May 15, 2025 Zeposia (ozanimod hydrochloride) BMY Primary completion Multiple Sclerosis Withdrawn ClinicalTrials.gov April 24, 2025 — BMY Earnings — Completed SEC 8-K Exhibit 99.1 April 21, 2025 — BMY PDUFA date — Scheduled SEC Form 10-K April 17, 2025 Camzyos® (mavacamten) BMY Label expansion — Approved openFDA Drugs@FDA April 17, 2025 Eliquis (apixaban) BMY Label expansion — Approved openFDA Drugs@FDA April 17, 2025 Eliquis (apixaban) BMY FDA approval — Approved openFDA Drugs@FDA April 8, 2025 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA April 8, 2025 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA February 6, 2025 — BMY Earnings — Completed SEC 8-K Exhibit 99.1 January 28, 2025 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA December 27, 2024 Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) BMY FDA approval — Approved openFDA Drugs@FDA October 3, 2024 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA September 26, 2024 Cobenfy (trospium chloride; xanomeline tartrate) BMY FDA approval To treat schizophreniaPress Release Approved FDA Novel Drug Approvals September 26, 2024 Opdivo® (nivolumab) BMY Advisory committee — Completed FDA advisory committee calendar September 26, 2024 Yervoy® (ipilimumab) BMY Advisory committee — Completed FDA advisory committee calendar August 30, 2024 Zeposia (ozanimod hydrochloride) BMY Label expansion — Approved openFDA Drugs@FDA June 21, 2024 Krazati (adagrasib) BMY Label expansion — Approved openFDA Drugs@FDA June 13, 2024 AUGTYRO (repotrectinib) BMY Label expansion — Approved openFDA Drugs@FDA March 15, 2024 ABECMA (idecabtagene vicleucel) BMY Advisory committee — Positive FDA advisory committee calendar March 6, 2024 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA January 26, 2024 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA November 15, 2023 AUGTYRO (repotrectinib) BMY FDA approval To treat ROS1-positive non-small cell lung cancer Approved FDA Novel Drug Approvals October 30, 2023 Orencia (abatacept) BMY Label expansion — Approved openFDA Drugs@FDA October 13, 2023 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA August 28, 2023 Reblozyl (luspatercept-aamt) BMY Label expansion — Approved openFDA Drugs@FDA June 15, 2023 Camzyos® (mavacamten) BMY Label expansion — Approved openFDA Drugs@FDA February 15, 2023 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA February 15, 2023 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA December 12, 2022 Krazati (adagrasib) BMY FDA approval — Approved FDA Novel Drug Approvals September 9, 2022 Sotyktu (deucravacitinib) BMY FDA approval To treat moderate-to-severe plaque psoriasis Approved FDA Novel Drug Approvals July 14, 2022 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 27, 2022 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 27, 2022 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA May 20, 2022 ONUREG (azacitidine) BMY Label expansion — Approved openFDA Drugs@FDA May 11, 2022 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 11, 2022 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA April 28, 2022 Camzyos® (mavacamten) BMY FDA approval To treat certain classes of obstructive hypertrophic cardiomyopathy Approved FDA Novel Drug Approvals March 22, 2022 Empliciti (elotuzumab) BMY Label expansion — Approved openFDA Drugs@FDA March 18, 2022 Opdualag (nivolumab; relatlimab-rmbw) BMY FDA approval To treat unresectable or metastatic melanoma Approved FDA Novel Drug Approvals March 4, 2022 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA December 15, 2021 Orencia (abatacept) BMY Label expansion — Approved openFDA Drugs@FDA August 19, 2021 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA July 30, 2021 Romidepsin (romidepsin) BMY Label expansion — Approved openFDA Drugs@FDA July 15, 2021 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 27, 2021 Zeposia (ozanimod hydrochloride) BMY Label expansion — Approved openFDA Drugs@FDA May 25, 2021 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA May 20, 2021 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA April 16, 2021 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA January 22, 2021 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA November 24, 2020 Idhifa (enasidenib mesylate) BMY Label expansion — Approved openFDA Drugs@FDA November 20, 2020 Pomalyst (pomalidomide) BMY Label expansion — Approved openFDA Drugs@FDA October 2, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA October 2, 2020 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA September 18, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA September 18, 2020 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA September 1, 2020 ONUREG (azacitidine) BMY FDA approval — Approved openFDA Drugs@FDA July 31, 2020 Evotaz (atazanavir sulfate; cobicistat) BMY Label expansion — Approved openFDA Drugs@FDA June 10, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 26, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 26, 2020 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA May 15, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA May 15, 2020 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA May 14, 2020 Pomalyst (pomalidomide) BMY Label expansion — Approved openFDA Drugs@FDA April 3, 2020 Reblozyl (luspatercept-aamt) BMY FDA approval — Approved openFDA Drugs@FDA March 25, 2020 Zeposia (ozanimod hydrochloride) BMY FDA approval — Approved openFDA Drugs@FDA March 10, 2020 Opdivo® (nivolumab) BMY Label expansion — Approved openFDA Drugs@FDA March 10, 2020 Yervoy® (ipilimumab) BMY Label expansion — Approved openFDA Drugs@FDA November 8, 2019 Reblozyl (luspatercept-aamt) BMY FDA approval — Approved openFDA Drugs@FDA August 16, 2019 Inrebic (fedratinib hydrochloride) BMY FDA approval — Approved openFDA Drugs@FDA August 1, 2017 Idhifa (enasidenib mesylate) BMY FDA approval — Approved openFDA Drugs@FDA January 17, 2012 Farxiga (dapagliflozin) BMY Complete Response Letter — CRL issued FDA Complete Response Letters
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from BMY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.